NPC 573 is a Bradykinin analog. NPC 573 inhibits contraction of the uterus.

NFE2L2 activator 3 (Compound 3) is a NFE2L2/NRF2 activator. NFE2L2 activator 3 specifically activates the NAD(P)H:quinone oxidoreductase (NQO1) enzyme, with its EC50 < 1 nM. NFE2L2 activator 3 can be used for research on respiratory system diseases such as chronic obstructive pulmonary disease.

NCO-650 free base is an antiallergic agent that acts by inhibiting tryptase, a key trypsin-like protease in mast cells. NCO-650 free base inhibits mast cell histamine release, increases intracellular cAMP levels in mast cells, suppresses bronchoconstriction, and prevents decreases in perfusion pressure and systemic blood pressure. NCO-650 free base is applicable to the research of allergic diseases and bronchial asthma.

Nav1.8-IN-21 is a potent and selective Nav1.8 inhibitor with analgesic activity. Nav1.8-IN-21 can be used for analgesia Research.

N3C14SOBRAC is a SOBRAC with an azide group at the end can be used in click chemical reactions. SOBRAC is an inhibitor of acidic ceramidase.

Multitarget AD-IN-7 is an orally active multi-target anti-AD compound. Multitarget AD-IN-7 exhibits inhibitory activity against GSK-3β and GSK-3α (IC50 = 0.66, 0.83 nM). Multitarget AD-IN-7 upregulates the expression of p-GSK-3β-Ser9, inhibits the phosphorylation of tau-Ser396, targets Aβ1-42, chelates pathogenic metal ions, scavenges ABTS•+, upregulates the expression of β-catenin and neurogenesis biomarkers, and promotes neurite outgrowth. Multitarget AD-IN-7 improves motor ability in Alzheimer's disease zebrafish. Multitarget AD-IN-7 is applicable to research related to Alzheimer's disease.

Multi-kinase-IN-11 (Compound 1a) is a DFG-out conformation-targeted multi-kinase inhibitor, including SRC, LCK, ABL, PYK2, CSK, HCK, P38 and C-KIT. Multi-kinase-IN-11 serves as a scaffold for the preparation of fluorescently labeled binding probes and affinity matrices.

MK 1256 is a highly selective and orally active inhibitor of tissue protease K (Cat K) with an IC50 of 0.62 nM. MK 1256 shows extremely high selectivity towards other tissue proteases (all > 1100 times), with only a slightly lower selectivity for tissue protease F (Cat F) (110 times). MK 1256 exhibits strong anti-bone resorption activity in the osteoporosis model of rhesus monkeys with ovariectomy. MK 1256 can be used for research on osteoporosis.

Minaxolone is a water-soluble steroid anesthetic agent.

Methyl 16(Z)-pentacosenoate is a fatty ester.

Methetoin is an anticonvulsant.

Menin-MLL-IN-36 (compound 398) is an inhibitor of menin/MLL protein/protein interaction with an IC50 value of 0.043 μM in MEIS1 mRNA expression. Menin-MLL-IN-36 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes.

Menin-MLL-IN-35 (compound 286) is an inhibitor of menin/MLL protein/protein interaction with an IC50 value of 0.096 μM in MEIS1 mRNA expression. Menin-MLL-IN-35 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes.

MDL 72832 (hydrochloride) is a 2,3-dihydro-1,4-benzodioxane derivative and a 5-HT1a receptor ligand with high affinity for the 5-HT1a receptor.

MCH-1623 is a nucleoside analog-derived, RNA-dependent RNA polymerase (RdRP) inhibitor. MCH-1623 interferes with viral RNA synthesis and exhibits broad-spectrum antiviral activity. MCH-1623 effectively inhibits the replication of vesicular stomatitis virus (VSV), influenza A virus (H1N1-PR8), human coronavirus OC43, human metapneumovirus (HMPV) and respiratory syncytial virus (RSV). Administered via inhalation, MCH-1623 exerts significant in vivo activity in mice, reducing pulmonary viral load and IL-6 levels, alleviating pulmonary tissue erythema, and significantly improving the survival rate of mice infected with lethal influenza virus. MCH-1623 can be used to investigate the infection mechanisms of various RNA viruses and for antiviral drug research.

Mapinastine is a biochemical assay reagent.

LASSBio-2389 is a selective ROCK2 inhibitor with an IC50 of 0.051 μM and an IC50 of 1.143 μM against ROCK1. LASSBio-2389 reduces the viability of MDA-MB-231 cells and inhibits cell migration. LASSBio-2389 is applicable to the research of triple-negative breast cancer.

LasB-IN-3 is a protease elastase (LasB) inhibitor of Pseudomonas aeruginosa with an IC50 value of 8.5 nM. LasB-IN-3 shows an IC50 of 58.9 nM for the Met128Val mutant. LasB-IN-3 binds to active sites of wild-type and Met128Val mutant LasB, coordinates zinc ions, forms hydrogen bonds and CH-π interactions, and inhibits LasB proteolytic activity. LasB-IN-3 increases survival rate in LasB-induced acute lung injury mice models. LasB-IN-3 can be used for the research of Pseudomonas aeruginosa infection.

Lantadene B is a triterpene component. Lantadene B can be isolated from the red variety of Lantana Camara. Lantadene B can be used in the research of cancer and inflammatory diseases.

KT-474 (KYM-001; PROTAC IRAK4 degrader-7) hydrochloride is an orally active PROTAC IRAK4 degrader with anti-tumor effects. KT-474 inhibits the cell cycle and induces apoptosis. KT-474 induces tumor regression in a xenograft model of MYD88-mutated ABC DLBCL. KT-474 is a click chemistry reagent, containing an alkyne group, which can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing azide groups.

KRASG12C IN-18 is an orally active covalent KRASG12C inhibitor that achieves complete covalent engagement of KRASG12C in both GDP- and GMPPNP-bound states and displays strong antiproliferative activity against KRASG12C and resistance-associated variants, including KRASG12C/R68S, with low-nanomolar IC50 values. KRASG12C IN-18 exhibits marked in vivo efficacy in KRASG12C-driven solid tumor and KRASG12C/R68S xenograft models and can be used for colorectal cancer research.

JHU-58 is a peptidomimetic agonist targeting mouse MRGPRC11 and rat MRGPRC receptors. JHU-58 demonstrates analgesic effects in mouse models of neuropathic pain. JHU-58 is promising for research of neuropathic pain.

JAK2-IN-20 is an orally active dual inhibitor targeting JAK2 kinase (IC50=49.17 nM) and influenza A virus PB2 protein (IC50=3.337 μM, Kd=2.82 μM). JAK2-IN-20 effectively blocks the JAK/STAT signaling pathway by reducing the phosphorylation levels of STAT1 and STAT3, thereby inhibiting viral replication and downregulating the expression of viral NP and PB2 proteins. In addition, JAK2-IN-20 significantly inhibits the mRNA expression of key inflammatory cytokines such as IL-6, TNF-α and IFN-β in inflammation and influenza infection models. JAK2-IN-20 serves as an important tool molecule for the study of influenza A virus infection and related pathologies.

HAT-IN-10 (Compound 12a) is an anti-human African trypanosomiasis (HAT) agent, with an EC50 value of 0.23 μM for T. brucei. HAT-IN-10 can be used for research on HAT.

GRK5-IN-5 (Compound 4a) is a selective G protein-coupled receptor (GPCR) kinase 5 (GRK5) inhibitor with an IC50 of 0.03 μM. GRK5-IN-5 shows IC50 values of 2.2 and 0.036 μM for GRK2 and GRK6. GRK5-IN-5 has potent anti-myocardial hypertrophy activity and also inhibits the proliferation of non-myocardial cells. GRK5-IN-5 can inhibit the abnormal upregulation of hypertrophy marker genes Nppa and Nppb, thus blocking pathological myocardial remodeling. GRK5-IN-5 can be used for the research of cardiac hypertrophy.

GMNN modulator-1 is a GMNN modulator.

Glaspimod is a haemoregulatory peptide.

GABRA5 modulator-1 is a GABRA5 modulator.

Fusidic acid prodrug is an antibacterial agent. Fusidic acid prodrug has significant antibacterial activity against Pseudomonas aeruginosa (MIC = 4 µg/mL). Fusidic acid prodrug can be used in the research of infectious conditions.

Fmoc-Gly-Gly-Phe-Gly-Paclitaxel (Compound 16a-3) is a drug-linker conjugates for ADC. Fmoc-Gly-Gly-Phe-Gly-Paclitaxel contains the ADC linker Fmoc-Gly-Gly-Phe-OH and a potent tubulin polymerization inhibitor Paclitaxel. Fmoc-Gly-Gly-Phe-Gly-Paclitaxel can be used for the research of cancer.